Nutritional Interventions in Amyotrophic Lateral Sclerosis: From Ketogenic Diet and Neuroprotective Nutrients to the Microbiota-Gut-Brain Axis Regulation.
Study Goal
The researchers aimed to explore the potential of the ketogenic diet as a complementary therapy for improving outcomes in ALS patients.
Results Summary
The abstract suggests that the ketogenic diet shows promise as a complementary therapy for ALS, alongside other emerging strategies like mitochondrial dysfunction targeting and neuroinflammation modulation. However, specific efficacy data or outcomes related to the ketogenic diet are not detailed.
Population
Patients with amyotrophic lateral sclerosis (ALS).
Effective Dosage
Not available
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
medications | decrease | disease progression | patients with amyotrophic lateral sclerosis | - | approved to slow | #1 |
targeting additional pathways such as mitochondrial dysfunction and neuroinflammation | increase | treatments | patients with amyotrophic lateral sclerosis | - | to develop more effective treatments | #2 |
personalized medicine, including genetic testing and biomarkers | increase | patient stratification and treatment tailoring | patients with amyotrophic lateral sclerosis | - | proving valuable in stratifying patients and tailoring treatment options | #3 |
nutritional interventions like the ketogenic diet and microbiome modulation | increase | therapeutic outcomes | patients with amyotrophic lateral sclerosis | - | show promise | #4 |
multidisciplinary approach that integrates early diagnosis, targeted treatments, and supportive care | increase | quality of life | patients with amyotrophic lateral sclerosis | - | to address the multisystemic nature of ALS and improve | #5 |
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with significant challenges in diagnosis and treatment. Recent research has highlighted the complex nature of ALS, encompassing behavioral impairments in addition to its neurological manifestations. While several medications have been approved to slow disease progression, ongoing research is focused on identifying new therapeutic targets. The current review focuses on emerging therapeutic strategies and personalized approaches aimed at improving patient outcomes. Recent advancements highlight the importance of targeting additional pathways such as mitochondrial dysfunction and neuroinflammation to develop more effective treatments. Personalized medicine, including genetic testing and biomarkers, is proving valuable in stratifying patients and tailoring treatment options. Complementary therapies, such as nutritional interventions like the ketogenic diet and microbiome modulation, also show promise. This review emphasizes the need for a multidisciplinary approach that integrates early diagnosis, targeted treatments, and supportive care to address the multisystemic nature of ALS and improve the quality of life for patients.